Skip to main content

Precipio Soars on Launch of COVID-19 Antibody Test on Amazon

Precipio says the test can only be purchased by qualified medical point-of-care providers.

Precipio  (PRPO) - Get Precipio Inc. Report skyrocketed Monday after the specialty diagnostics company said it had launched its COVID-19 rapid antibody test on Amazon's  (AMZN) - Get Inc. Report business platform.

Shares of the New Haven, Conn., company were soaring 93% to $3.52 on Monday.

The 20-minute antibody test, which is made by Nirmidas Biotech in Palo Alto, Calif., was the first U.S.-based test to receive emergency use authorization by the U.S. Food and Drug Administration for point-of-care, the company said in a statement.

Dow Posts Solid Gain on First Trading of May and Nasdaq Eases

The purpose of this test is to identify the presence of antibodies that have been developed after the person has been exposed to the virus, or has been vaccinated.

Antibodies are the body’s natural biological response to an infection or vaccination, and their development begins the body’s process of building immunity to protect against future infections.

People unknowingly infected or those who know they were infected can determine if they now have those antibodies, the company said. 

Scroll to Continue

TheStreet Recommends

In addition, individuals who have been vaccinated can use the test to inform whether the vaccination was successful and if the antibodies measured have persisted over time.

Precipio said the product is visible for sale on Amazon’s website and app, but it may currently be purchased only by qualified medical point-of-care providers.

Physicians and other medical facilities can buy these items directly from Amazon, the company said, and receive them within two business days.

Last month, the FDA granted emergency-use authorization to COVID-19 tests made by Abbott Laboratories  (ABT) - Get Abbott Laboratories Report and Quidel  (QDEL) - Get QuidelOrtho Corp Com Report.

Chembio Diagnostics  (CEMI) - Get Chembio Diagnostics Inc. Report launched a test in April that can differentiate between COVID-19 and influenza.

Moderna  (MRNA) - Get Moderna Inc. Report said last month that its COVID-19 vaccine generated antibodies that lasted at least six months after the second dose in a small-sample size study.

Amazon is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells AMZN? Learn more now.